Viking Therapeutics (VKTX) Misses Q4 EPS by 12c

Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($0.56), $0.12 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight